Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“One of the biggest challenges in hematologic oncology isn’t a lack of data – it’s bringing all of that information together to make the right decision for the patient.
A new study introduces HemaGuide, an AI agent designed to support multidisciplinary tumor board decision-making in hematologic malignancies.
Rather than functioning as a chatbot, HemaGuide:
- Converts unstructured clinical records into structured case summaries.
- Incorporates molecular profiling.
- Grounds recommendations in disease-specific guidelines and a library of >2,000 real-world tumor board cases.
- Routes cases based on complexity (guideline-based, advanced, or molecular).
The results were impressive:
- 82.8% concordance with prospective tumor board decisions.
- 81.8% concordance across 555 external validation cases spanning 47 hematologic disease entities.
- Hallucination rate of just 0.3%.
- Median processing time of 39 seconds on standard hardware.
Perhaps most interesting, resident physicians using the system achieved decision-making that approached senior hematologists and in some settings even outperformed specialists working outside their primary area of expertise.
This doesn’t replace multidisciplinary tumor boards or clinical judgment. But it highlights how AI may help extend expert-level decision support to centers that don’t have immediate access to disease-specific expertise.
As hematology becomes increasingly driven by genomics, biomarkers, and rapidly evolving evidence, tools like this could help make specialized care more accessible while keeping physicians firmly in the loop.”
Title: Clinical decision support in hematological malignancies using a case-grounded AI agent
Authors: Julian Zoller, Michael Kalz, Xuewei Wu, Sven Cuntz, Linus Kruk, Niklas Kehl, Julius J. Michel, Cornelius Funk, Sarah Richter, Tobias Tix, David Sedloev, Jonathan Naboschni, Jan H. Frenking, Silvia Barbosa, Oliver L. Saldanha, Alanna Kirschner, Anna D. Metzler, Antonia Schach, René Onken, Tim R. Wagner, Martin Dugas, Andreas Trumpp, Martin Dreyling, Michael von Bergwelt-Baildon, Kai Rejeski, Tim Sauer, Peter Dreger, Marc S. Raab, Carsten Müller-Tidow, Jakob N. Kather, Mirco J. Friedrich
Read The Full Article
Other articles about Hematologic Oncology on OncoDaily.